Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 Inflammasome formation

Cardiology (Switzerland)

Volumn 126, Issue 1, 2013, Pages 1-11

  Wang, Yongliang ^a   Wu, Yongquan ^a   Chen, Jiawei ^a   Zhao, Shumei ^a   Li, Hongwei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hypertension; Left ventricular remodeling; Myocardial fibrosis; NLRP3 inflammasome; Pirfenidone; Transverse aortic constriction

Indexed keywords

COLLAGEN; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; HYALURONIC ACID; HYDROGEN PEROXIDE; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATORY CELL; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; SURVIVAL RATE; THORACIC CAVITY; WESTERN BLOTTING; CELL INFILTRATION; CHRONIC INFLAMMATION; RAT; TRANSVERSE AORTA CONSTRICTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRIER PROTEINS; COLLAGEN; CONSTRICTION; FIBROSIS; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; MYOCYTES, CARDIAC; MYOFIBROBLASTS; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 84879763603     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000351179     Document Type: Article

References (20)

1. Ma C, Chen S, You L, Luo Z, Xing C: Development and psychometric evaluation of the Treatment Adherence Questionnaire for Patients with Hypertension. J Adv Nurs 2012; 68: 1402-1413.
2. Todiere G, Aquaro GD, Piaggi P, Formisano F, Barison A, Masci PG, Strata E, Bacigalupo L, Marzilli M, Pingitore A, Lombardi M: Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2012; 60: 922-929.
3. Ashrafian H, McKenna WJ, Watkins H: Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res 2011; 109: 86-96.
4. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, Gonzalez A, Colan SD, Seidman JG, Diez J, Seidman CE: Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010; 363: 552-563.
5. Richeldi L, Yasothan U, Kirkpatrick P: Pirfenidone. Nat Rev Drug Discov 2011; 10: 489-490.
6. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB: Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011; 22: 1144-1151.
7. Garcia L, Hernandez I, Sandoval A, Salazar A, Garcia J, Vera J, Grijalva G, Muriel P, Margolin S, Armendariz-Borunda J: Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002; 37: 797-805.
8. Yamazaki T, Yamashita N, Izumi Y, Nakamura Y, Shiota M, Hanatani A, Shimada K, Muro T, Iwao H, Yoshiyama M: The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res 2012; 35: 34-40.
9. Strowig T, Henao-Mejia J, Elinav E, Flavell R: Inflammasomes in health and disease. Nature 2012; 481: 278-286.
10. Rathinam VA, Vanaja SK, Fitzgerald KA: Regulation of inflammasome signaling. Nat Immunol 2012; 13: 333-332.
11. Artlett CM: Inflammasomes in wound healing and fibrosis. J Pathol 2013; 229: 157-167.
12. Bernardo BC, Gao XM, Winbanks CE, Boey EJ, Tham YK, Kiriazis H, Gregorevic P, Obad S, Kauppinen S, Du XJ, Lin RC, McMullen JR: Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci USA 2012; 109: 17615-17620.
13. Maass AH, Buvoli M: Cardiomyocyte preparation, culture, and gene transfer. Methods Mol Biol 2007; 366: 321-330.
14. Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu S, Wei Y: In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One 2011; 6:e28134.
15. Susic D, Fares H, Frohlich ED: Nebivolol prevents myocardial fibrosis and diastolic dysfunction in salt-loaded spontaneously hypertensive rats. J Am Soc Hypertens 2012; 6: 316- 323.
16. Velten M, Duerr GD, Pessies T, Schild J, Lohner R, Mersmann J, Dewald O, Zacharowski K, Klaschik S, Hilbert T, Baumgarten G, Meyer R, Boehm O, Knuefermann P: Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice. Cardiovasc Res 2012; 96: 422-432.
17. Tschopp J, Schroder K: NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010; 10: 210-215.
18. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD: The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
19. Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, de Boer RA, Sillje HH: The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PLoS One 2010; 5:e12963.
20. Azibani F, Devaux Y, Coutance G, Schlossarek S, Polidano E, Fazal L, Merval R, Carrier L, Solal AC, Chatziantoniou C, Launay JM, Samuel JL, Delcayre C: Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. PLoS One 2012; 7:e38197.